Novo Nordisk Invests $4bn to Expand US Production for Ozempic and Wegovy

, the maker of Ozempic, is investing over $4 billion in expanding its manufacturing operations in the US. The pharmaceutical company plans to build a new plant in North Carolina to produce its diabetes drug Ozempic and weight-loss product Wegovy. This significant investment of $4.1 billion will go towards constructing a second filling and finishing facility in Clayton, North Carolina. is making this move to meet the increasing demand for its obesity and diabetes medications, which are administered through pre-filled pens and require weekly injections. This expansion in manufacturing capacity represents one of the largest investments in 's history as it strives to keep pace with the growing market for its innovative drugs.